Rate of implant failure in patients on antiresorptive drugs: a clinical investigation
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Aim The present study is to determine unsuccessful implant cases associated to bisphosphonates and also discuss the etiopathogenesis of medication-related osteonecrosis of the jaw in such patients.
Materials and methods A total of 40 conventional dental implants were placed in 26 patients with a history of antiresorptive drugs therapy. Candidates were asked for any previous history of medicine related osteonecrosis of the jaw (MRONJ). Platelet rich growth factor, allograft and resorbable collagen membrane were used as adjunct measures to the specific sites. RFA (ostell) value was recorded at baseline as well as after sixth month in all cases. The mean follow-up of the study was 42.1 months.
Results Out of a total of 40 implants, 8 failed to integrate. We did not encounter any case of osteonecrosis of jaw but healing was delayed in one patient.
Conclusion The outcome of this study shows that success rate seems to be no different than in patients without a history of bisphosphonate treatment but there may be an added risk of implant failure in patients who are on antiresorptive drugs.
Copyright (c) 2020 Ariesdue
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Journal of Osseointegration has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.